ISSN: 1556-0864
Journal Home
Journal Guideline
Journal of Thoracic Oncology Q1 Unclaimed
Journal of Thoracic Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 161. It has an SJR impact factor of 5,866 and it has a best quartile of Q1. It has an SJR impact factor of 5,866.
Journal of Thoracic Oncology focuses its scope in these topics and keywords: lung, cancer, patients, smallcell, cell, nsclc, treatment, chemotherapy, expression, malignant, ...
Type: Journal
Type of Copyright:
Languages:
Open Access Policy:
Type of publications:
Publication frecuency: -
- €
Inmediate OANPD
Embargoed OA- €
Non OAMetrics
5,866
SJR Impact factor161
H Index207
Total Docs (Last Year)975
Total Docs (3 years)5376
Total Refs8338
Total Cites (3 years)497
Citable Docs (3 years)9.09
Cites/Doc (2 years)25.97
Ref/DocOther journals with similar parameters
Annual Review of Public Health Q1
Annual Review of Pathology: Mechanisms of Disease Q1
The Lancet Global Health Q1
Annual Review of Clinical Psychology Q1
JAMA - Journal of the American Medical Association Q1
Compare this journals
Aims and Scope
Best articles by citations
Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer
View moreP2.01-011 The Efficiency and Safety of Apatinib plus S-1 as Second-Line or Laterline Chemotherapy for Advanced Squamous Cell Lung Carcinoma
View moreSalvage Surgery After Stereotactic Radiotherapy: A New Challenge for Thoracic Surgeons
View moreLong-Term Active Surveillance of Screening Detected Subsolid Nodules is a Safe Strategy to Reduce Overtreatment
View moreOptimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung Cancer
View moreMultidisciplinary Management of Lung Cancer
View moreBody Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium
View moreOA18.03 Safety and Clinical Activity of Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Advanced Thymic Epithelial Tumors (TETs)
View moreRole of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database
View moreDifferences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-Small Cell Lung Cancer
View moreProgram Committee
View moreAcetylcholine Receptor Pathway and Lung Cancer
View moreComparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience
View moreSteering Committee
View moreRandomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer
View moreAlpha-Actinin 4 Is Associated with Cancer Cell Motility and Is a Potential Biomarker in Non-Small Cell Lung Cancer
View moreVariations in Receipt of Curative-Intent Surgery for Early-Stage Non-Small Cell Lung Cancer (NSCLC) by State
View moreLungs Don't Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers
View moreHistone Deacetylase, Proteasome, and Heat Shock Protein Inhibitors for the Treatment of Lung Cancer
View moreFibroblast Growth Factor Inhibitors
View moreImpact of interleukin-22 on K-ras mutant lung cancer promotion and stemness properties
View moreProlonged Survival in Patients with Lung Cancer with Diabetes Mellitus
View moreThe International Association for the Study of Lung Cancer International Staging Project on Lung Cancer
View moreNovel Taxanes/Epothilones
View more
If you are a journal editor you can claim the journal profile and add new information for the visitors.
Comments